State of New Jersey Common Pension Fund D Has $2.85 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)


State of New Jersey Common Pension Fund D boosted its stake in CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) by 16.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,404 shares of the company’s stock after buying an additional 6,263 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in CRISPR Therapeutics were worth $2,850,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Elkhorn Partners Limited Partnership boosted its stake in CRISPR Therapeutics by 180.0% in the 4th quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock valued at $27,000 after buying an additional 225 shares in the last quarter. IronBridge Private Wealth LLC acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at $30,000. First PREMIER Bank acquired a new stake in CRISPR Therapeutics in the 1st quarter valued at $31,000. Sterling Investment Advisors Ltd. boosted its stake in CRISPR Therapeutics by 50.0% in the fourth quarter. Sterling Investment Advisors Ltd. now owns 600 shares of the company’s stock worth $45,000 after purchasing an additional 200 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in CRISPR Therapeutics by 443.8% in the first quarter. Allworth Financial LP now owns 609 shares of the company’s stock worth $38,000 after purchasing an additional 497 shares in the last quarter. Institutional investors and hedge funds own 56.12% of the company’s stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $75.91, for a total value of $1,897,750.00. Following the completion of the sale, the chief executive officer now directly owns 290,279 shares in the company, valued at $22,035,078.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on CRSP shares. Citigroup reduced their price objective on CRISPR Therapeutics from $64.00 to $53.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 17th. Needham & Company LLC reduced their price objective on CRISPR Therapeutics from $170.00 to $122.00 in a research note on Friday, May 13th. Royal Bank of Canada reduced their price objective on CRISPR Therapeutics from $95.00 to $85.00 in a research note on Tuesday, May 10th. Credit Suisse Group assumed coverage on CRISPR Therapeutics in a research note on Thursday, April 28th. They issued a “neutral” rating and a $78.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on CRISPR Therapeutics in a research note on Thursday, June 16th. They set an “outperform” rating and a $98.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $114.31.

CRISPR Therapeutics Trading Down 1.2 %

NASDAQ CRSP opened at $75.00 on Friday. The stock has a 50-day simple moving average of $68.36 and a 200 day simple moving average of $62.73. The company has a market capitalization of $5.81 billion, a PE ratio of 20.78 and a beta of 1.91. CRISPR Therapeutics AG has a 12 month low of $42.51 and a 12 month high of $142.64.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.91) by ($0.41). The company had revenue of $0.94 million during the quarter, compared to the consensus estimate of $2.45 million. CRISPR Therapeutics had a net margin of 34.04% and a return on equity of 12.77%. The company’s revenue for the quarter was up 74.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.51) EPS. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -8.98 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Read more here: Source link